Collegium Pharmaceutical Inc (COLL) Stock Analysis
Verdict: HOLD
High-margin ADHD expansion via AZSTARYS faces market skepticism from $857.8M debt leverage and opioid pain franchise cliff.
Investment score: 52/100
Analysis as of
Is Collegium Pharmaceutical Inc stock worth reviewing? AI model thesis
The AI model rates COLL a HOLD. Robust cash generation from pain therapies and fast-growing ADHD assets (Jornay PM + AZSTARYS) are weighed down by $857.8M in total debt and Q2 2026 GAAP losses.
7-factor investment score
- Valuation: 68/100 (weight 20%)
- Financial Health: 45/100 (weight 15%)
- Technical Momentum: 25/100 (weight 15%)
- Earnings Quality: 65/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 50/100 (weight 15%)
Collegium Pharmaceutical Inc opportunities and risks
What speaks for COLL
- ADHD Franchise Diversification with AZSTARYS and Jornay PM
What speaks against COLL
- Severe Balance Sheet Debt Overhang Following $650M Acquisition
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| COLL | 14.7x | 0.9x | 2.5x | 60.0% | 5.9% | 44.9% |
| SGP | n/a | 0.0x | n/a | 0.0% | 0.0% | -5.5% |
| LXRX | n/a | 19.2x | n/a | 98.9% | -147.4% | -10.0% |
| ACRS | n/a | 87.5x | n/a | 95.6% | -921.5% | -8.6% |
| CRMD | 3.3x | 1.3x | 2.0x | 82.8% | 40.5% | 40.9% |
| Peer median | n/a | 10.3x | n/a | 89.2% | -73.7% | -7.1% |
Frequently asked questions about Collegium Pharmaceutical Inc (COLL)
Is COLL stock a good investment?
The cached TradeMates AI model rates Collegium Pharmaceutical Inc as HOLD with an investment score of 52/100. The AI model rates COLL a HOLD. Robust cash generation from pain therapies and fast-growing ADHD assets (Jornay PM + AZSTARYS) are weighed down by $857.8M in total debt and Q2 2026 GAAP losses. This is algorithmic model output, not personal investment advice.
Is COLL stock a buy?
The TradeMates model verdict for COLL is HOLD with an investment score of 52/100. Treat this as a model signal to review, not a personal buy recommendation.